Publications by authors named "Patric Nelson"

Claim this Profile
E
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
Dirk J Blom, Michael J Koren, Eli Roth, Maria Laura Monsalvo, C Stephen Djedjos, Patric Nelson

Diabetes Obes Metab· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, Jonathan Fialkow, Joel M Neutel, Patric Nelson

JAMA· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, Jonathan Fialkow, Joel M Neutel, Patric Nelson

Clin Cardiol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Michael J Koren, Robert P Giugliano, Frederick J Raal, David Sullivan, Michael Bolognese, Patric Nelson

Circulation· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Patric Nelson

Diabetes Care· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Patric Nelson, Terri Poon, Xuesong Guan, Catherine Schnabel, Matthew Wintle

Diabetes Technol Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
Terri Poon, Patric Nelson, Larry Shen, Michael Mihm, Kristin Taylor

Diabetes Technol Ther· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis